Cronos Group (STU:7CI) Shareholder Yield % : 2.47% (As of Mar. 2026)


STU:7CI Cronos Group Inc STU:7CI
85 GF Score
Price €2.47
GF Value €3.07
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Cronos Group Shareholder Yield %?

Cronos Group STU:7CI -1.04% 85 Shareholder Yield % is 2.47% as of Mar. 2026. GuruFocus rates STU:7CI with a GF Score™ of 85/100 and a GF Value™ of €3.07 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 973 Drug Manufacturers companies, Cronos Group ranks better than 68.24% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Cronos Group's Shareholder Yield % was 2.47%.


Cronos Group  (STU:7CI) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Cronos Group Shareholder Yield % Related Terms


Cronos Group Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Cronos Group's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cronos Group Shareholder Yield % Chart

Cronos Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.17 0.51 0.11 1.00

Cronos Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.54 0.53 1.00 2.77

STU:7CI vs ZTS, UTHR: Shareholder Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cronos Group Shareholder Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Cronos Group's Shareholder Yield % falls into.


STU:7CI
85GF Score
Cronos Group Inc STU:7CI
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cronos Group Shareholder Yield % Calculation

Cronos Group's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+2.74 %+0.05 %
=2.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of 2.47% mean?
Cronos Group (STU:7CI) has a Shareholder Yield % of 2.47% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #309 out of 973 companies in the Drug Manufacturers industry, placing it in the top 31.8%.
Is Cronos Group's Shareholder Yield % too high?
Cronos Group's current Shareholder Yield % is 2.47%. The Drug Manufacturers industry median Shareholder Yield % is 0.30. Cronos Group's value of 2.47% is 723.3% above this industry median. Based on the distribution chart, Cronos Group ranks #309 out of 973 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cronos Group has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #309 out of 973 companies for Shareholder Yield %. This puts Cronos Group in the upper half of its industry. The industry median Shareholder Yield % is 0.30. Cronos Group's value of 2.47% is 723.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current Shareholder Yield % of 2.47% is 723.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current Shareholder Yield % is 2.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (STU:7CI) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.07, compared to a current price of €2.47 — trading 19.7% below its estimated fair value. The current Shareholder Yield % is 2.47% and 723.3% above the Drug Manufacturers industry median of 0.30. Cronos Group's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Cronos Group (STU:7CI), the current Shareholder Yield % is 2.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cronos Group (STU:7CI) Overvalued in 2026?

Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued. The current stock price of €2.47 is trading 19.7% below its estimated GF Value™ of €3.07. GuruFocus considers Cronos Group to be Modestly Undervalued.

Key valuation signals for STU:7CI:

  • Shareholder Yield %: 2.47%
  • GF Value™: €3.07 vs. price of €2.47 (19.7% below fair value)
  • GF Score™: 85/100 with 1 warning sign
  • Industry Position: 723.3% above the Drug Manufacturers median (#309 of 973)

No single metric tells the full story. See the STU:7CI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cronos Group Business Description

Other Exchanges CRON:USACRON:Canada
Address 4491 Concession Rd 12, Stayner, ON, CAN, L0M 1S0
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
85GF Score

Get the complete analysis for STU:7CI

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.47
Price
€3.07
GF Value